Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 6Small Cell Lung Carcinoma 3Stomach Neoplasms 2Solid Tumor Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Cancer Patients 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Efficacy and Safety 1Carcinoma, Ovarian Epithelial 1Advanced Small Intestine Cancer 1

Interventions

irinotecan sucrosofate 1camrelizumab 1Radiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Rectal Cancer Patients × irinotecan sucrosofate × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡